Economic Evaluation of rhIL-11 (Ⅰ) and rhTPO in the Treatment of Thrombocytopenia Caused by Chemotherapy
- VernacularTitle:重组人白介素-11(Ⅰ)与重组人促血小板生成素治疗化疗相关血小板减少的经济学评价
- Author:
Fangjun CHEN
;
Dan ZHANG
;
Zeng WANG
;
Nengming LIN
- Publication Type:Journal Article
- Keywords:
rhIL-11(Ⅰ);
rhTPO;
Lung cancer;
Gemcitabine;
Thrombocytopenia;
Cost-minimization analysis
- From:
China Pharmacist
2015;(2):250-252
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and pharmacoeconomics of rhIL-11(Ⅰ) and rhTPO in the treatment of thrombocy-topenia caused by gemcitabine chemotherapy in lung cancer patients. Methods:A retrospective analysis was used. Totally 58 hospital-ized lung cancer patients who suffered thrombocytopenia caused by gemcitabine chemotherapy and treated with rhIL-11(Ⅰ) or rhTPO from June 2011 to June 2014 were involved in the study, and the efficacy and pharmacoeconomics of rhIL-11(Ⅰ) and rhTPO were e-valuated and compared. Results:The lowest platelet value after the chemotherapy in rhIL-11(Ⅰ) group was higher than that in rhTPO group (P<0. 01), and the platelet decrease time in rhIL-11(Ⅰ) group was shorter than that in rhTPO group (P<0. 01), while the platelet qualified rate of the two groups showed no statistically significant difference (P>0. 05). The results of cost-minimization anal-ysis showed that the average cost of rhIL-11(Ⅰ) group was lower than that of rhTPO group(P<0. 01), furthermore, the average cost of the patients with GP, GC or the other gemcitabine chemotherapy regimens in rhIL-11 (Ⅰ) group was lower than that in rhTPO group. Conclusion:The effect of rhIL-11 (Ⅰ) in the treatment of thrombocytopenia caused by gemcitabine based-chemotherapy in lung cancer patients is not inferior to that of rhTPO, and shows certain advantages in economic cost.
